Drug Trial Radar · NCT05669755
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
7,101
Actual
Start
Mar 1, 2023
Primary completion
Sep 1, 2027
Study completion Oct 14, 2027
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.
Conditions
- Cardiovascular Disease
Interventions
CagrilintideDrug
Participants will receive cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
SemaglutideDrug
Participants will receive semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
PlaceboDrug
Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal strokeTime frame: From baseline (week 0) to end of study (up to 242 weeks or more)
Locations
633 sites in 25 countries. Site status is shown where the registry gives one.
Univ of Alabama Birmingham
Birmingham, Alabama
Chambliss Clinical Trials LLC
Montgomery, Alabama
Honor Health
Scottsdale, Arizona
National Heart Institute Cal
Beverly Hills, California
Valley Clinical Trials
Covina, California
Scripps Wht Diab Inst La Jolla
La Jolla, California
First Valley Medical Group
Lancaster, California
Clinical Trials Research_Sacramento
Lincoln, California
Torrance Clin Res Inst, Inc.
Lomita, California
Pacific Clinical Studies
Los Alamitos, California
Monterey Endocrine & Diabetes Institute, Inc
Monterey, California
Valley Clinical Trials, Inc.
Northridge, California
Desert Oasis Hlthcr Med Group
Palm Springs, California
Western University of Health Sciences
Pomona, California
Linda Vista Health Care Ctr
San Diego, California
N America Res Inst - San Dimas
San Dimas, California
Encompass Clinical Research_Spring Valley
Spring Valley, California
Lundquist Inst.-Biom Inno-UCLA
Torrance, California
Bridgeport Hospital
Bridgeport, Connecticut
Innovative Research of W FL
Clearwater, Florida
Florida Premier Cardiology
Delray Beach, Florida
Fleming Island Center for Clinical Research
Fleming Island, Florida
Life Spring Research Foundation LLC
Miami, Florida
Oceane 7 Medical & Research Center, Inc.
Miami, Florida
Reyes Clinical Research, Inc
Miami, Florida
San Marcus Res Clin Miami Lakes
Miami Lakes, Florida
Floridian Clinical Research, LLC
Miami Lakes, Florida
Adult Medicine of Lake County, Inc
Mt. Dora, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
Center for Diab,Obes & Metab
Pembroke Pines, Florida
Hanson Clinical Research Center
Port Charlotte, Florida
Northeast Research Institute
Saint Augustine, Florida
Cardio Partners Clin Res Inst
Wellington, Florida
Endo Res Solutions Inc
Roswell, Georgia
Atlanta Heart Specialists, LLC
Tucker, Georgia
Rocky Mountain Diab&Osteo Ctr
Idaho Falls, Idaho
Northwest Heart Clinical Research, LLC
Arlington Heights, Illinois
Macoupin Research Group
Gillespie, Illinois
Clinical Invest Special_Gurnee
Gurnee, Illinois
Endeavor Health
Skokie, Illinois
Showing 40 of 633 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.